|
|
|
|
Tuesday, May 12, 2020
Ceapro (CRPOF)(CZO:CA)
Research Initiation-Pursuing Novel Nutraceutical and Biopharmaceutical Markets
Ceapro, Inc. is a publicly-held (TSX-V: CZO, OTCQX: CRPOF) Canadian biotechnology company developing and commercializing “active ingredients” for the healthcare and cosmetic industries. Ceapro’s active ingredients are primarily derived from oats and other renewable plant resources. The Company utilizes its proprietary plant extraction-based manufacturing process to supply active ingredients based on “oat beta glucan and avenanthramides”. Ceapro has patented a technology known as “Pressurized Gas eXpanded (PGX) technology”, which has superior features when compared to conventional drying and purification technologies. Using PGX technology, Ceapro generates novel biopolymers and biocomposites with micro/nanoparticles.
Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Initiating Coverage. We are initiating research coverage on Ceapro, Inc.
Revenue Generating Biotechnology Company. Ceapro is a commercial stage Canadian biotechnology company selling active ingredients for the personal care, cosmetic and healthcare industries. In F2019, the Company generated total revenue of $12.9 mm (11% growth) and CFO of $0.9 mm. Ceapro’s active ingredients are used by household name brands in the personal care markets including Johnson & Johnson’s Aveeno line of products, Neutrogena, and Lubriderm.
Transition to become a Biopharmaceutical Company. While continuing to grow its active ingredients base business, Ceapro’s management plans to leverage its proprietary PGX manufacturing technology to develop novel products based on oat beta glucan and avenanthramides to pursuit nutraceutical, cosmeceutical and
Get the full report on Channelchek desktop.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.